Vaccinations versus Lockdowns to Prevent COVID-19 Mortality.

Vaccines (Basel)

Departments of Health Policy and Management, Industrial Engineering and Management, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Published: August 2022

Measures employed to combat COVID-19 included public lockdowns and vaccination campaigns. Israel's extensive public health system produced data demonstrating the real-world results of these measures. Our objective was to evaluate the health and economic outcomes of the measures to cope with COVID-19. Publicly available datasets from the Israeli Ministry of Health were used to model the parameters of the pandemic in Israel. The Oxford COVID-19 Government Response Tracker was used for quantitative data on government policies. Data on the Israeli economy were taken from the Central Bureau of Statistics. Our models demonstrate that the first lockdown prevented 1022 COVID-19 deaths at the cost of 36.4-38.6 billion NIS. The second lockdown prevented 1970 COVID-19 deaths and cost 18-21 billion NIS. These lifesaving effects were observed with a time lag from the declaration of lockdown. The primary vaccination campaign cost 1 billion NIS and prevented 4750 COVID-19 deaths. The first vaccination booster campaign prevented 650 COVID-19 deaths and cost 51.1 million NIS. Therefore, the cost per prevented COVID-19 death is 10-36 million NIS with a national lockdown versus 210,000 NIS in the primary vaccination campaign and 79,000 NIS in the first booster campaign. In conclusion, both lockdowns and vaccination campaigns effectively lower COVID-19 deaths, but the cost to avoid one COVID-19 death with effective vaccination is 50-466 times lower than with a lockdown.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413824PMC
http://dx.doi.org/10.3390/vaccines10081347DOI Listing

Publication Analysis

Top Keywords

covid-19 deaths
20
deaths cost
16
billion nis
12
covid-19
11
lockdowns vaccination
8
vaccination campaigns
8
lockdown prevented
8
primary vaccination
8
vaccination campaign
8
booster campaign
8

Similar Publications

Background: SHEN26 (ATV014) is an oral RNA-dependent RNA polymerase (RdRp) inhibitor with potential anti-SARS-CoV-2 activity. Safety, tolerability, and pharmacokinetic characteristics were verified in a Phase I study. This phase II study aimed to verify the efficacy and safety of SHEN26 in COVID-19 patients.

View Article and Find Full Text PDF

Decoding the SARS-CoV-2 Infection Process: Insights into Origin, Spread, and Therapeutic Approaches.

Microb Pathog

January 2025

Department of Bioengineering, Faculty of engineering, Integral University, Lucknow-226026, India. Electronic address:

Globally, over 768 million confirmed cases and 6.9 million deaths had been documented as of July 17, 2023. Coronaviruses have a relatively large RNA genome.

View Article and Find Full Text PDF

Background: Evidence from preclinical studies suggests that IL-6 signalling has the potential to modulate immunopathogenic mechanisms upstream of autoantibody effector mechanisms in patients with generalised myasthenia gravis. We aimed to assess the safety and efficacy of satralizumab, a humanised monoclonal antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis.

Methods: LUMINESCE was a randomised, double-blind, placebo-controlled, multicentre, phase 3 study at 105 sites, including hospitals and clinics, globally.

View Article and Find Full Text PDF

Subphenotypes of Long COVID and the clinical applications of probiotics.

Biomed Pharmacother

January 2025

School of Medical and Life Sciences, Sunway University, Petaling Jaya, Selangor 47500, Malaysia. Electronic address:

As the number of infections and deaths attributable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues to rise, it is now becoming apparent that the health impacts of the Coronavirus disease (COVID-19) may not be limited to infection and the subsequent resolution of symptoms. Reports have shown that patients with SARS-CoV-2 infection may experience multiple symptoms across different organ systems that are associated with adverse health outcomes and develop new cardiac, renal, respiratory, musculoskeletal, and nervous conditions, a condition known as Long COVID or the post-acute sequelae of COVID-19 (PASC). This review provides insights into distinct subphenotypes of Long COVID and identifies microbiota dysbiosis as a common theme and crucial target for future therapies.

View Article and Find Full Text PDF

Background: Acute kidney injury (AKI) is common in critically ill patients and is associated with increased morbidity and mortality. Its complications often require renal replacement therapy (RRT). Invasive mechanical ventilation (IMV) and infections are considered risk factors for the occurrence of AKI.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!